Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?

Creative Commons License

Elverdi T., Özer Çerme M. D., Aydın T., Eşkazan A. E.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY, vol.14, no.10, pp.1183-1188, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Editorial Material
  • Volume: 14 Issue: 10
  • Publication Date: 2021
  • Doi Number: 10.1080/17512433.2021.1944102
  • Journal Name: EXPERT REVIEW OF CLINICAL PHARMACOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, MEDLINE
  • Page Numbers: pp.1183-1188
  • Keywords: Anticoagulant, antiplatelet, bleeding, caplacizumab, thrombosis, thrombotic thrombocytopenic purpura, VENOUS THROMBOEMBOLISM, PLASMA-EXCHANGE, COMPLICATIONS, DIPYRIDAMOLE, GUIDELINES, MANAGEMENT, INFUSION
  • Open Archive Collection: AVESIS Open Access Collection
  • Istanbul University-Cerrahpasa Affiliated: Yes